The editors of Mast Cell Biology, Drs. Gilfillan and Metcalfe, have enlisted an outstanding group of investigators to discuss the emerging concepts in mast cell biology with respect to development of these cells, their homeostasis, their activation, as well as their roles in maintaining health on the one hand and on the other, their participation in disease.
Extensively illustrated and liberally laced with clinically helpful tools, Clinical Adult Neurology is an affordable reference for all clinicians and residents. With emphasis on diagnostic tools and strategies as well as management pearls and perils, Clinical Adult Neurology will meet the needs of all health care practitioners caring for patients with neurologic disorders. The book is organized into three sections, with Section 1 covering all aspects of neurologic evaluation, Section 2 describing common clinical problems in neurology, and Section 3 discussing all aspects of neurologic diseases. All sections and chapters emphasize the clinical approach to the patient with consistently useful pedagogical tools, including Features tables for diagnostic help with all neurologic diseases, Pearls and Perils boxes that represent pithy distillations of clinical wisdom from leading experts, Key Clinical Questions boxes that help clinicians frame patient diagnosis and management; and annotated bibliographies that highlight the most important references for further study. The book s organization, format, and features all stress the efficient and well-rationed use of medical care for patients with neurologic disease. Succinct content presentations make all information easy to locate and digest. The format will also be a helpful tool for those preparing for examinations.
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise. Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech’s improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech’s science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech’s founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits. Integrating the scientific, the corporate, the contextual, and the personal, Genentech tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it. 
Recently, the first "zoopharming" product has reached market approval: it is a recombinant human protein for medical use that is produced in the milk of transgenic goats. In addition, other transgenic animals, including faster-growing salmon and „environmentally friendly" pigs with reduced levels of phosphate in their faeces are awaiting regulatory approval. These are only some examples of upcoming applications of genetic engineering in farm animals. Other potential applications include traditional breeding goals such as higher milk or meat yields, leaner meat, and disease resistance. While genetic engineering in livestock opens a huge range of possibilities, it also brings about concerns of safety and justification: does genetic engineering affect animal welfare? Is it safe and morally acceptable to apply genetic engineering to farm animals for the various purposes that are envisaged?
It is against this background that the Europäische Akademie GmbH and the Berlin-Brandenburgische Akademie der Wissenschaften addressed the topic of transgenic farm animals in an interdisciplinary symposium in 2007. In these proceedings the following topics are covered: an analysis of the state of the art of the technology and its applications, an introduction to the specific application zoopharming (including its historical industrial development and the market for biopharmaceuticals), an assessment of ethical aspects, and considerations regarding the investigation of animal welfare implications of livestock biotechnology. The proceedings address science, industry, politics and the general public interested in the chances and risks of this upcoming field of biotechnology.
I turned to this book to get background on the biotech industry. A cursory review of the material showed me the topics were there. However, the book really needed editing for both clarity and style. Yes, the introduction may have been by a Nobel Laureate, but that doesn't mean it didn't need editing. Actually, there is the same introduction in all the books in the series.
Science Books Copyright © 2011 | Template created by O Pregador | Powered by Blogger